Balaxi Pharmaceuticals Ltd Performance
Day's Low
Day's High
₹75.98₹7852 Week's Low
52 Week's High
₹74₹151.45
| Returns % | |
| 1 Month Return | -16.75 % |
| 3 Month Return | -29.65 % |
| 1 Year Return | -6.04 % |
| Market Stats | |
| Previous Close | ₹74.81 |
| Open | ₹78.00 |
| Volume | 10.15K |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹428.80Cr |
Balaxi Pharmaceuticals Ltd Key Statistics
| P/E Ratio | 11.51 |
| PEG Ratio | 1.31 |
| Market Cap | ₹428.80 Cr |
| P/B Ratio | 4.59 |
| EPS | -0.438 |
| Dividend Yield | 0 |
| Sector | Pharmaceuticals |
| ROE | 3.42 |
Balaxi Pharmaceuticals Ltd Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| NA | ₹428.80 Cr | 83.63% | 0.56 | -₹3 Cr | ₹241 Cr | |
| NA | ₹4,808.85 Cr | 36.95% | 0.52 | -₹30 Cr | ₹1,369 Cr | |
| NA | ₹7.91 Cr | 29.88% | 0.90 | NA | NA | |
| NA | ₹4,498.32 Cr | 355.76% | 0.50 | ₹33 Cr | ₹204 Cr | |
| NA | ₹0.00 Cr | -12.22% | 0.77 | NA | NA |
About Balaxi Pharmaceuticals Ltd
In March 2017, Balaxi Overseas Pvt Ltd acquired 16,700,036 (54.94%) equity shares of the company along with its control and management. Its representatives became the new directors and the company was renamed to Balaxi Ventures. A preferential issue of 6,960,000 equity shares was approved in July 2019 and allotted in August, increasing the company’s paid-up share capital to Rs 100,000,000. Following this, Balaxi Ventures started international wholesale trading in pharmaceutical products, builders hardware, and recently launched YAP food products.
Share Price: ₹77.67 per share as on 14 Nov, 2024 04:01 PM
Market Capitalisation: ₹428.80Cr as of today
Revenue: ₹77.38Cr as on September 2024 (Q3 24)
Net Profit: ₹4.59Cr as on September 2024 (Q3 24)
Listing date: 30 Nov, 2015
Chairperson Name: Ashish Maheshwari
| Organisation | Balaxi Pharmaceuticals Ltd |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
Key events for Balaxi Pharmaceuticals Ltd
Balaxi Pharma Reports Mixed Financial Results - 06 Nov, 2024
Balaxi Pharma's consolidated net sales for September 2024 rose 41.41% to Rs 77.38 crore, while net profit fell 68.19% to Rs 4.59 crore. The stock has seen a decline of 25.82% over the last six months.
Insights on Balaxi Pharmaceuticals Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 3 quarters, 59.14 Cr → 73.27 Cr (in ₹), with an average increase of 10.1% per quarter
- POSITIVE IMPACT
Retail Holding Up
Retail Investor have increased holdings from 17.11% to 17.50% in Sep 2024 quarter
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 65.99% of holdings in Sep 2024 quarter
NEGATIVE IMPACTPrice Dip
In the last 3 months, BALAXI stock has moved down by -29.7%
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 5 quarters, 14.43 Cr → 4.59 Cr (in ₹), with an average decrease of 23.8% per quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 16.88% to 16.48% in Sep 2024 quarter
Balaxi Pharmaceuticals Ltd Financials
Balaxi Pharmaceuticals Ltd Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 65.99% | 0.00 | |
| Foreign Institutions | 16.48% | ||
| Mutual Funds | 0% | 0.00 | |
| Retail Investors | 17.5% | 2.33 | |
| Others | 0.02% | 0.00 |
Balaxi Pharmaceuticals Ltd Key Indicators
Balaxi Pharmaceuticals Ltd Valuation
Balaxi Pharmaceuticals Ltd in the last 5 years
Lowest (-263.96x)
May 28, 2024
Today (11.51x)
November 14, 2024
Industry (54.87x)
November 14, 2024
Highest (66.45x)
September 21, 2020
Balaxi Pharmaceuticals Ltd Earnings and Dividends
Balaxi Pharmaceuticals Ltd Earnings Results
Balaxi Pharmaceuticals Ltd’s net profit fell -68.19% since last year same period to ₹4.59Cr in the Q2 2024-2025. On a quarterly growth basis, Balaxi Pharmaceuticals Ltd has generated -29.17% fall in its net profits since last 3-months.
Read More about Earnings ResultsBalaxi Pharmaceuticals Ltd Dividends May,2022
In the quarter ending March 2022, Balaxi Pharmaceuticals Ltd has declared dividend of ₹0.50 - translating a dividend yield of 0.64%.
Read More about Dividends
Balaxi Pharmaceuticals Ltd Technicals Summary
Bearish
Neutral
Bullish
Balaxi Pharmaceuticals Ltd is currently in a Bearish trading position according to technical analysis indicators.
FAQs on Balaxi Pharmaceuticals Ltd
- Get a PAN card.
- Open a Demat account.
- Open a Trading account.
- Link your Demat account to your Trading account.
- Fund your Trading account.
- Place an order to buy Balaxi Pharmaceuticals Ltd shares.
Balaxi Pharmaceuticals Ltd (BALAXI) share price today is ₹77.67
Balaxi Pharmaceuticals Ltd is listed on NSE
Balaxi Pharmaceuticals Ltd is not listed on BSE
- Today’s highest price of Balaxi Pharmaceuticals Ltd is ₹78.
- Today’s lowest price of Balaxi Pharmaceuticals Ltd is ₹75.98.
PE Ratio of Balaxi Pharmaceuticals Ltd is 11.51
PE ratio = Balaxi Pharmaceuticals Ltd Market price per share / Balaxi Pharmaceuticals Ltd Earnings per share
Today’s traded volume of Balaxi Pharmaceuticals Ltd(BALAXI) is 10.15K.
Today’s market capitalisation of Balaxi Pharmaceuticals Ltd(BALAXI) is ₹428.8Cr.
| Balaxi Pharmaceuticals Ltd(BALAXI | Price |
|---|---|
52 Week High | ₹151.45 |
52 Week Low | ₹74 |
Balaxi Pharmaceuticals Ltd(BALAXI) share price is ₹77.67. It is down -48.72% from its 52 Week High price of ₹151.45
Balaxi Pharmaceuticals Ltd(BALAXI) share price is ₹77.67. It is up 4.96% from its 52 Week Low price of ₹74
| Balaxi Pharmaceuticals Ltd(BALAXI | Returns |
|---|---|
1 Day Returns | 2.86% |
1 Month Returns | -16.75% |
3 Month Returns | -29.65% |
1 Year Returns | -6.04% |